


Searching News Database: targeted drug delivery
HSMN NewsFeed - 4 Jan 2021
Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing
Flowonix Medical, Inc. and SWK Holdings Corporation Announce Closing of $33 Million Financing
HSMN NewsFeed - 14 Oct 2019
Magnetic Insight Announces the Appointment of David Panzarella as Chief Commercial Officer
Magnetic Insight Announces the Appointment of David Panzarella as Chief Commercial Officer
HSMN NewsFeed - 6 Dec 2018
Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors
Genisphere Appoints Biopharmaceutical Veteran, Brian P. McVeigh, to Its Board of Directors
HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
HSMN NewsFeed - 2 Sep 2015
Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer
Atossa Genetics, Inc. Announces Appointment of Scott Youmans as Chief Operating Officer
HSMN NewsFeed - 31 Aug 2015
Flowonix Medical, Inc. Announces First Use of Its Patient Therapy Controller (PTC(TM))
Flowonix Medical, Inc. Announces First Use of Its Patient Therapy Controller (PTC(TM))
HSMN NewsFeed - 13 Jan 2014
Mallinckrodt Pharmaceuticals and Medtronic Announce Clinical and Commercial Collaboration
Mallinckrodt Pharmaceuticals and Medtronic Announce Clinical and Commercial Collaboration
HSMN NewsFeed - 15 Mar 2012
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
Medtronic Receives Health Canada License for Deep Brain Stimulation Therapy in Refractory Epilepsy Patients
HSMN NewsFeed - 2 Sep 2009
Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
Potential Breakthrough Cancer Treatment Now Available From Vascular Designs
HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Additional items found! 10
Members Archive contains
10 additional stories matching:
targeted drug delivery
(Password required)
targeted drug delivery
(Password required)
